Osteoporosis Treatment Guidelines

Diagnosis and Treatment Recommendations

The American College of Radiology recommends that a patient with a spine T-score of -2.91 should be treated with a bone-modifying agent such as an oral bisphosphonate, intravenous bisphosphonate, or subcutaneous denosumab to reduce fracture risk 1, 2
The patient has osteoporosis based on the spine T-score of -2.91, which meets the WHO definition of osteoporosis (T-score ≤ -2.5) 3, 2
The diagnostic classification is based on the lowest T-score at any of the recommended DXA regions, which in this case is the spine at -2.91 4, 5

Oral bisphosphonates are recommended as first-line therapy due to their efficacy, safety profile, and cost-effectiveness 6
Risedronate (Actonel) 35mg once weekly or 150mg once monthly is a recommended oral bisphosphonate option 7
Ibandronate (Boniva) 150mg once monthly is a recommended oral bisphosphonate option 7
Zoledronic acid (Reclast) 5mg IV once yearly is a highly effective option in preventing bone loss and building bone mass 1

Calcium and vitamin D supplementation is recommended, with a target serum vitamin D level of at least 20 ng/mL (50 nmol/L) 1, 6
Calcium supplementation should be 1,200mg daily (diet plus supplements) 1
Vitamin D supplementation should be 800-1,000 IU daily 6
Weight-bearing exercises, resistance training, and balance exercises to reduce fall risk are recommended 1

Bone mineral density testing should be repeated every 2 years to assess treatment efficacy 1, 8
A significant change in BMD is considered 1.1% or greater 8

The presence of degenerative changes in the lumbar spine may artificially elevate BMD measurements, potentially masking the true degree of bone loss 3, 2
QCT is particularly useful for patients with extensive degenerative disease of the spine, as it can isolate trabecular bone and avoid the cortical bone that may be affected by degenerative changes 3

Denosumab should not be discontinued without transitioning to another antiresorptive agent due to risk of rebound bone loss 7

Failure to address calcium and vitamin D deficiency before initiating pharmacologic therapy is a common pitfall to avoid 1, 6
Discontinuing denosumab without a transition plan can lead to rapid bone loss and increased fracture risk 7